Targeting delivery in Parkinson's disease

Newland, Benjamin ORCID: https://orcid.org/0000-0002-5214-2604, Dunnett, Stephen B. ORCID: https://orcid.org/0000-0003-1826-1578 and Dowd, Eilís 2016. Targeting delivery in Parkinson's disease. Drug Discovery Today 21 (8) , pp. 1313-1320. 10.1016/j.drudis.2016.06.003

Preview

PDF - Accepted Post-Print Version Download (871kB) | Preview

Abstract

Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Medicine Pharmacy
Publisher:	Elsevier
ISSN:	1359-6446
Date of First Compliant Deposit:	31 October 2017
Date of Acceptance:	14 June 2016
Last Modified:	02 Dec 2024 21:45
URI:	https://orca.cardiff.ac.uk/id/eprint/106085

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item